Overactive Bladder News Archive
In a phase 2 trial, treatment with an acetaminophen-ibuprofen combination was associated with a significant reduction in nocturnal voids and improved quality of life compared with placebo.
In a study, 8 mg of silodosin daily for 12 weeks was associated with a significant reduction in nocturia episodes.
A recent paper provides 8 questions to ask patients to elicit information that enables targeted treatment of nocturia.
Small study found that 2 mg of melatonin taken at bedtime did not significantly decrease the mean number of nocturia episodes vs placebo.
Women presenting with lower urinary tract symptoms cluster into 4 distinct symptom groups, according to a recent study.
Bladder hydrodistention with fulguration of Hunner lesions reduced nocturia in IC patients with or without nocturnal polyuria.
Treatment appeared to reduce fall risk among older adults.
Study confirms associations between nocturia and older age, female sex, overactive bladder, and diabetes.
Men experiencing 3 or more nocturia episodes per night had a 43% increased mortality risk in adjusted analyses.
In a study, only 5% of nocturia and nocturnal polyuria were prescribed oral desmopressin.
Clinicians tend to focus on the number of voids, but patients worry more about interrupted sleep.
Rather intermittent oxygen desaturation was associated with a 3% greater likelihood of nocturia.
In clinical trials, the combination of Myrbetriq + solifenacin succinate was associated with greater improvements in the number of incontinence episodes per 24 hours (primary endpoint), the number of micturations per 24 hours (primary endpoint), and the volume voided per micturation (secondary endpoint) compared to placebo or to individual active components.
Thicker bladder wall and a tower-shaped curve on uroflowmetry are associated with shorter healing periods among pediatric patients with overactive bladder.
More patients taking desmopressin decreased their nightly voiding episodes by half or more.
Clinicians' choice of treatment highly correlated with a diagnosis based on urodynamic studies.
At least half of women using tibial nerve stimulation or pelvic floor muscle training experienced fewer night awakenings, according to a new study.
Metabolic syndrome and smoking are associated with 2.5- and 1.7-fold increased odds of moderate or severe nocturia in men with BPH/LUTS.
In a study, men with sleep disorders were 23% and 27% more likely to report nocturia and daytime LUTS than men without sleep disorders.
At baseline, women reported an average of 3.9 urgency incontinence episodes per day and 1.3 episodes of nocturia per night.
In a 12-month study, men with prostate cancer treated with ADT reported more nocturia episodes than men with prostate cancer treated with prostatectomy alone and men with no history of cancer.
Methylene blue aids observation of the procedure and assessment of drug distribution.
Clinicians should be alert to the relationship between antimuscarinics usage and depressive disorder in OAB women and provide appropriate instructions for these patients.
Onabotulinumtoxin A successfully reduced urinary frequency and urgency, but not urgency urinary incontinence episodes.
Pharmacologic properties of oxybutynin may cause significant cognitive side effects in elderly persons.
Treatment discontinuation rate is lower than that of traditional antimuscarinics, study finds.
Only a quarter of men receiving injections of BoNT-A comply with the treatment long-term.
Prospective study reveals a 1-year surgical intervention rate of 13%.
Consistent mean reductions in urinary incontinence; durable improvements in quality of life.
De novo OAB — defined as urgency with or without frequency and nocturia — developed in some patients.
Reoperation rate for transvaginal mesh prolapse surgery is 4%.
These same patients, however, had less intense detrusor overactivity, urodynamic evaluation revealed.
Urologists and gynecologists are 49% and 30% more likely than primary care doctors to prescribe second-generation agents.
Potentially inappropriate medication use is prevalent in older adults undergoing antimuscarinic treatment for overactive bladder.
Patients' median bladder capacity improved from 150 to 200 mL and continence improved in nearly 90% of patients.
Researchers also find a significant association between smoking and secondary nocturnal enuresis.
A high cure rate was observed in women with de novo OAB symptoms following transobturator tape surgery.
Symptom improvement was greater in patients receiving tamsulosin plus darifenacin compared with tamsulosin monotherapy.
Adding vaginal estrogen may sustain the effects.
Among seniors with severe overactive bladder, a combination of solifenacin and mirabegron decreased incontinence by an average 3.5 episodes a day.
The number of neuromodulation test procedures performed per physician has increased.
Small reductions in urge incontinence episodes, voids per day with daily dose of medications.
A study found that 33.8% of women received anticholinergics compared with 19.4% of men.
OAB treatment is associated with a decreased risk of falls, study finds.
Regardless of delivery type, obesity ups the risk of more severe urinary symptoms, study shows.
In a study, severe nocturia predicted increased mortality risk.
Elderly patients with OAB may benefit from combined high-dosage antimuscarinics.
Repeat injections of onabotulinumtoxinA (BTXA) appear to benefit patients with non-neurogenic overactive bladder.
Improvements in efficacy and quality of life last at least six months, study finds.
Depression risk greater for men with nocturia than for women with nocturia.
Two studies show significant reduction in number of nocturnal voids for women.
In most responders, overactive bladder symptom improvement sustained to three years.
Products advertised through fax; not FDA approved.
Oxytrol is intended for use by those 18 and older.
Increasing the daily dose from 5 to 10 mg resulted in reductions in mean total urgency score and mean micturition frequency.
The FDA has approved onabotulinumtoxinA (Botox) as a treatment for overactive bladder (OAB) in adults who are inadequately managed with anticholinergic medications.
Patients with type 2 diabetes are twice as likely as nondiabetics to suffer from the condition.
Mirabegron is the first oral OAB drug with a distinct mechanism of action to be approved in three decades.
Flexible-dose fesoterodine is superior to placebo in decreasing the number of nocturnal urgency episodes and nocturnal micturitions in patients with overactive bladder (OAB), researchers reported at the American Urological Association 2012 annual meeting.
Patients with overactive bladder (OAB) say they are most bothered by symptoms of urinary urgency either as a primary complaint or as a driving symptom for frequency, according to a pilot study presented at the American Urological Association 2012 annual meeting.
Diabetes has no influence on intravesical botulinum toxin type A (BoNTA) injection in overactive bladder (OAB) patients, researchers reported at the American Urological Association 2012 annual meeting.
A new oxybutynin gel (OTG) with propylene glycol to aid transdermal delivery, which dispensed via a pump, is effective for treating urgency and mixed urinary incontinence (UI), according to the findings of a phase 3 study presented at the American Urological Association 2012 annual meeting.
Men and women with overactive bladder (OAB) are significantly less likely to achieve recommended physical activity levels than those with no or minimal symptoms (NMS) of OAB, according to a poster presentation at the American Urological Association 2012 annual meeting.
Watson Pharmaceuticals of Parsippany, N.J., and Antares Pharma. Inc. of Ewing, NJ, have announced the launch of Gelnique (oxybutynin), a transdermal gel for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and frequency.
PARIS—Mirabegron, an experimental drug for overactive bladder (OAB), can effectively treat the condition in patients whether or not they failed previous antimuscarinic therapy, according to findings presented at the 27th Annual Congress of the European Association of Urology.
Repeated injections of botulinum toxin type A (BoNTA) are safe and effective for the medium-term management of refractory overactive bladder (OAB) and idiopathic detrusor overactivity (IDO), according to British investigators.
Metabolic syndrome is associated with overactive bladder (OAB) in women, according to researchers.
GLASGOW—Intravesical botulinum toxin may be an effective treatment for overactive bladder (OAB) without detrusor overactivity (DOA) on urodynamic assessment, researchers reported at the International Continence Society annual meeting.
If cleared by the FDA, mirabegron would be the first oral treatment with a new mechanism of action for OAB in almost 30 years.
GLASGOW—Antibiotics may be a useful adjunctive treatment for overactive bladder (OAB), according to British researchers.
WASHINGTON, D.C.—Trigonal intradetrusor injections of botulinum toxin-A (BTX-A) results in greater reduction in overactive bladder (OAB) symptoms compared with trigone-sparing BTX-A injections, Irish investigators reported at the American Urological Association 2011 annual meeting.
WASHINGTON, D.C.—Posterior compartment pelvic organ prolapse (POP) in women is often associated with overactive bladder (OAB), and POP surgery may help to decrease OAB symptoms as well as detrusor overactive (DO), according to study findings presented at the American Urological Association 2011 annual meeting.
WASHINGTON, D.C.—Urinary nerve growth factor (NGF) and MCP-1 may be surrogate markers for monitoring age-associated biochemical changes in patients with overactive bladder (OAB), according to data presented at the American Urological Association 2011 annual meeting.
WASHINGTON, D.C.—Questionnaires used to diagnose patients with overactive bladder (OAB) may identify anyone with polyuria, bladder hypersensitivity, and even OAB-wet with rare leakage episodes as OAB-dry, investigators reported at the American Urological Association 2011 annual meeting.
WASHINGTON, D.C—Japanese researchers found that more than one fifth of patients with type 2 diabetes receiving care at a dedicated diabetes center have overactive bladder (OAB).
WASHINGTON, D.C.—Nocturia is the most common overactive bladder (OAB) symptom affecting health-related quality of life (HRQL) in patients with postural tachycardia syndrome (POTS), investigators reported at the American Urological Association 2011 annual meeting.
WASHINGTON, D.C.—Overactive bladder (OAB) symptoms are common in patients with Parkinson's disease regardless of age and gender, and the severity of Parkinson's symptoms correlates with OAB symptoms, according to a study presented at the American Urological Association 2011 annual meeting.
WASHINGTON, D.C.—Elevation of serum leptin and a decrease in monocyte chemotactic protein-1 (MCP-1) levels are associated with overactive bladder (OAB) symptoms, according to new data presented at the American Urological Association 2011 annual meeting.
WASHINGTON, D.C.—Sacral neuromodulation with InterStim Therapy is safe and well tolerated as a treatment for patients with overactive bladder and those with urinary retention, French investigators reported at the American Urological Association 2011 annual meeting.
WASHINGTON, D.C.—Adverse events (AEs) after intravesical botulinum toxin type A for idiopathic detrusor overactivity (IDO) are encountered frequently, according to a new study presented at the American Urological Association 2011 annual meeting.
WASHINGTON, D.C.—Detrusor botulinum toxin type A injections are a safe and effective treatment long-term for patients with severe overactive bladder (OAB), Swiss researchers reported at the American Urological Association 2011 annual meeting.
WASHINGTON, D.C.—Men and women who suffer from overactive bladder (OAB) report significantly greater levels of work limitations compared with those without urinary symptoms, according to a new study presented at the American Urological Association 2011 annual meeting.
WASHINGTON, D.C.—The natural history of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) may involve as much remission as progression, according to a new longitudinal study presented at the American Urological Association 2011 annual meeting.
WASHINGTON, D.C.—Overactive bladder (OAB) is highly prevalent in both women and men and the prevalence varies by race and ethnicity, according to study findings presented at the American Urological Association 2011 annual meeting.
VIENNA—Findings from a large randomized trial confirm the effectiveness of botulinum toxin type A (BoNT-A) for refractory idiopathic detrusor overactivity (IDO) in women.
SAN FRANCISCO—Healthy lifestyle choices, such as not smoking and exercising regularly, may significantly impact urinary and sexual function, two studies suggest.
In a recent study, fesoterodine showed rapid onset of efficacy at one week in patients with overactive bladder (OAB) who were previously treated with tolterodine and dissatisfied with that drug.
TORONTO—An analysis of gene-expression patterns in women with overactive bladder (OAB) may point the way to possible new biomarkers for the condition.
SAN FRANCISCO—Increasing levels of C-reactive protein (CRP) are associated with increasing odds of overactive bladder (OAB), according to a population-based study of men and women.
Percutaneous tibial nerve stimulation (PTNS) is safe and effective for treating overactive bladder (OAB) symptoms, a recent study shows.
The associated cost is a potential reason for undertreatment.
Only 24.4% of patients aged 45 years and older take drugs for the condition, according to researchers.
Study findings at 12 months showed prolonged significant improvements in objective urinary parameters.
Solifenacin-treated patients experienced less dry mouth than those taking oxybutynin immediate release.
Percutaneous tibial nerve stimulation may be considered an alternative treatment for overactive bladder (OAB), researchers reported in the Journal of Urology (2009;182:1055-1061).
Uroplasty, Inc., a medical device company with headquarters in Minnetonka, Minn., has received a patent for its Urgent PC Neuromodulation System and stimulation methods for treating overactive bladder (OAB).
Researchers have reported encouraging results from a small study examining intravesical instillation of a botulinum toxin/dimethyl sulfoxide (DMSO) solution as a treatment for refractory idiopathic overactive bladder (OAB).
Watson Pharmaceuticals, Corona, Calif., has received approval for Gelnique (oxybutynin chloride) Gel 10%, the first and only topical gel for the treatment of overactive bladder (OAB).
The procedure is ideal in this population because it is minimally invasive and highly efficacious
Increased bladder sensation and detrusor overactivity are the most frequent urodynamic findings of overactive bladder (OAB) in women with diabetes, researchers in Taiwan reported in Neurourology and Urodynamics (2009; published online ahead of print).
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)